DigiStain – the UK’s First Breast Cancer Risk Profiling Technology
Digistain for patients is a patented risk profiling test for hormone receptor-positive breast cancer patients approved by the UK’s Medicines & Healthcare products Regulatory Agency. It reports thelikelihood of breast cancer recurrence when treated with hormone therapy alone.
Digistain is designed for patients who have been diagnosed with invasive breast cancer who are Stage 1 or 2, HER2-, ER+ or < 3 malignant lymph nodes. It provides a 10 Year Risk of Recurrence Breast Cancer Risk Report with detailed information on your result, for the best course action and treatment.
Digistain Prognostic Score
Unlike first-generation genomic tests used in hospitals around the world today, Digistain works biologically downstream to measure markers at the protein level. It, therefore, avoids the quality control and reproducibility issues common to RNA isolation from formalin-fixed tissue.
The advantage of working downstream is that Digistain’s unique approach is much closer to the patient-outcome than biologically upstream laboratory protocols and is robust to clinical protocol variabilities.
In a recent landmark trial of over 840 patients, Digistain’s Prognostic Score demonstrated unequivocal equivalence to the best-in-class genomics tests in use today.
Subscribe to leading news and insights
To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.